Kemp, P. M., & Cliburn, K. D. (2015). Comparison of Species-Specific β-Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine (Report No. DOT/FAA/AM-15/6). United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute. https://rosap.ntl.bts.gov/view/dot/57190
Kemp, Philip M. and Kacey D Cliburn. Comparison of Species-Specific β-Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine. Report no. DOT/FAA/AM-15/6. United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute, 2015. https://rosap.ntl.bts.gov/view/dot/57190.
Kemp, Philip M., and Kacey D Cliburn Comparison of Species-Specific β-Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine. United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute, 2015, Report no. DOT/FAA/AM-15/6, ROSA P. https://rosap.ntl.bts.gov/view/dot/57190.
Toxicological investigations of fatal aviation accidents include testing for ∆9 -tetrahydrocannabinol (THC), the active component of marijuana, and its major metabolite, 11-nor-9-carboxy-∆9 -THC (THCCOOH) in postmortem fluids and tissues from deceased pilots. These cannabinoids, as well as others, exist in human urine as their glucuronide conjugates, formed during Phase II metabolism to increase their solubility for excretion. Prior to the analysis of cannabinoids in urine by gas chromatography/mass spectrometry (GC-MS), it is desirable to cleave (hydrolyze) the glucuronic acid to enhance the detection of the unconjugated compounds. In the current study, β-glucuronidases from 3 mollusk species (Helix pomatia, Patella vulgate, and Haliotis rufescens), 1 bacteria (Escherichia coli), and bovine liver were compared for their quantitative efficiency in hydrolyzing the glucuronide bond in spiked, blank urine.
Kemp, P. M., & Cliburn, K. D. (2015). Comparison of Species-Specific β-Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine (Report No. DOT/FAA/AM-15/6). United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute. https://rosap.ntl.bts.gov/view/dot/57190
Kemp, Philip M. and Kacey D Cliburn. Comparison of Species-Specific β-Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine. Report no. DOT/FAA/AM-15/6. United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute, 2015. https://rosap.ntl.bts.gov/view/dot/57190.
Kemp, Philip M., and Kacey D Cliburn Comparison of Species-Specific β-Glucuronidase Hydrolysis of Cannabinoid Metabolites in Human Urine. United States. Department of Transportation. Federal Aviation Administration. Office of Aviation. Civil Aerospace Medical Institute, 2015, Report no. DOT/FAA/AM-15/6, ROSA P. https://rosap.ntl.bts.gov/view/dot/57190.
ROSA P serves as an archival repository of USDOT-published products including scientific
findings, journal articles, guidelines, recommendations, or other information authored or co-authored by
USDOT or funded partners. As a repository, ROSA P retains documents in their original published format to
ensure public access to scientific information.
Links with this icon indicate that you are leaving a Bureau of Transportation
Statistics (BTS)/National Transportation Library (NTL)
Web-based service.
Thank you for visiting.
You are about to access a non-government link outside of
the U.S. Department of Transportation's National
Transportation Library.
Please note: While links to Web sites outside of DOT are
offered for your convenience, when you exit DOT Web sites,
Federal privacy policy and Section 508 of the Rehabilitation
Act (accessibility requirements) no longer apply. In
addition, DOT does not attest to the accuracy, relevance,
timeliness or completeness of information provided by linked
sites. Linking to a Web site does not constitute an
endorsement by DOT of the sponsors of the site or the
products presented on the site. For more information, please
view DOT's Web site linking policy.
To get back to the page you were previously viewing, click
your Cancel button.